Clinical Trial for Parkinson's Disease Using Allogeneic HB-adMSCs (Early and Moderate PD)

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 16, 2021

Primary Completion Date

December 15, 2025

Study Completion Date

January 15, 2026

Conditions

Parkinson Disease

Interventions

BIOLOGICAL

Biological/Vaccine: Allogeneic HB-adMSCs

HB-adMSCs will be administered intravenously to study participants who qualify.

OTHER

Placebo

Sterile Saline Solution 0.9%

Trial Locations (1)

Hope Biosciences Stem Cell Research Foundation, Sugar Land

All Listed Sponsors

lead

Hope Biosciences Research Foundation

INDUSTRY

NCT04995081 - Clinical Trial for Parkinson's Disease Using Allogeneic HB-adMSCs (Early and Moderate PD) | Biotech Hunter | Biotech Hunter